Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5049-5057

  Xue, Mei ^a,b   Zhang, Liang ^c   Yang, Ming Xing ^a   Zhang, Wei ^a   Li, Xiu Min ^a,b   Ou, Zhi Min ^a   Li, Zhi Peng ^a,b   Liu, Su Huan ^a   Li, Xue Jun ^a   Yang, Shu Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Berberine; Fatty liver; Hepatosteatosis; Solid lipid nanoparticles

Indexed keywords

ACYL COENZYME A DESATURASE; ALANINE AMINOTRANSFERASE; BERBERINE; CARNITINE PALMITOYLTRANSFERASE I; FAT DROPLET; FATTY ACID SYNTHASE; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; LIPID; NANOPARTICLE; SCD1 PROTEIN, MOUSE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CARNITINE PALMITOYLTRANSFERASE 1 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; FATTY ACID SYNTHASE GENE; FATTY LIVER; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; LIPID METABOLISM; LIPID STORAGE; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEAROYL COA DESATURASE GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C GENE; UPREGULATION; WEIGHT CHANGE; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; ORGAN SIZE;

MUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BERBERINE; BODY WEIGHT; CARNITINE O-PALMITOYLTRANSFERASE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FATTY ACID SYNTHASES; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; NANOPARTICLES; ORGAN SIZE; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES; UP-REGULATION;

EID: 84939615423     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S84565     Document Type: Article

References (28)

1. Yang J, Ljn J. [Advance on study in anti-tumor mechamism of bererine (Ber)]. Zhongguo Zhong Yao Za Zhi. 2007;32(10):881-934.Chinese.
2. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126(1):5-17.
3. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148-E156.
4. Li X, Li Z, Xue M, et al. Fructus Xanthii attenuates hepatic steatosis in rats fed on high-fat diet. PLoS One. 2013;8(4):e61499.
5. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007;44(4): 931-937.
6. Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci. 2009;98(11):4391-4401.
7. Liu YT, Hao HP, Xie HG, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38(10):1779-1784.
8. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81(7):680-689.
9. Xue M, Yang MX, Zhang W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677-4687.
10. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339-350.
11. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147-152.
12. Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci. 2008; 53(3):785-788.
13. Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids. 2011;2011:783-976.
14. Iizuka K, Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J. 2008;55(4):617-624.
15. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res. 2009;50 Suppl: S74-S79.
16. Xue-jun Li, Mei Xue, Shu-yu Yang, inventor. The First Affiliated Hospital of Xiamen University, assignee. A kind of berberine hydrochloride solid lipid nanoparticle pharmaceutics and its preparation method. China Patent CN201210495674.4. 2013 Mar 6.
17. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308(1):143-155.
18. Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos. 2004;32(4):405-412.
19. Xia CQ, Liu N, Miwa GT, Gan LS. Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos. 2007;35(4): 576-582.
20. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos. 2009;37(6): 1172-1178.
21. Liu Y, Zhang L, Song H, Ji G. Update on berberine in nonalcoholic fatty liver disease. Evid Based Complement Alternat Med. 2013;2013: 308134.
22. Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011;13(4):376-388.
23. Sun W, Bi Y, Liang H, et al. Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine. 2011;39(3): 235-241.
24. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem. 2000;275(42):32379-32382.
25. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest. 1997;99(5):846-854.
26. Jeong HW, Lee JW, Kim WS, et al. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma. Diabetes. 2011;60(2):496-506.
27. Xue M, Zhao Y, Li XJ, et al. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats. Eur J Pharm Sci. 2012;47(4):713-717.
28. Caliceti C, Rizzo P, Cicero AF. Potential benefits of berberine in the management of perimenopausal syndrome. Oxid Med Cell Longev. 2015; 2015:723093.